

# Computer aided detection of tuberculosis on chest radiographs: An evaluation of the CAD4TB v6 system

Keelin Murphy<sup>1,\*</sup>, Shifa Salman Habib<sup>2</sup>, Syed Mohammad Asad Zaidi<sup>2</sup>, Saira Khowaja<sup>3,4</sup>, Aamir Khan<sup>3,4</sup>, Jaime Melendez<sup>5</sup>, Ernst T. Scholten<sup>1</sup>, Farhan Amad<sup>2</sup>, Steven Schalekamp<sup>1</sup>, Maurits Verhagen<sup>6</sup>, Rick H. H. M. Philipsen<sup>5</sup>, Annet Meijers<sup>5</sup>, and Bram van Ginneken<sup>1</sup>

<sup>1</sup>Radboud University Medical Center, 6525 GA, Nijmegen, the Netherlands

<sup>2</sup>Community Health Solutions, Karachi, 74000, Pakistan

<sup>3</sup>Interactive Research and Development, Karachi, 75190, Pakistan

<sup>4</sup>The Indus Health Network, Karachi, 75190, Pakistan

<sup>5</sup>Thirona, 6525 EC, Nijmegen, the Netherlands

<sup>6</sup>Universal Delft Ltd., Ghana

\*Keelin.Murphy@radboudumc.nl

## ABSTRACT

There is a growing interest in the automated analysis of chest X-Ray (CXR) as a sensitive and inexpensive means of screening susceptible populations for pulmonary tuberculosis. In this work we evaluate the latest version of CAD4TB, a software platform designed for this purpose. Version 6 of CAD4TB was released in 2018 and is here tested on an independent dataset of 5565 CXR images with GeneXpert (Xpert) sputum test results available (854 Xpert positive subjects). A subset of 500 subjects (50% Xpert positive) was reviewed and annotated by 5 expert observers independently to obtain a radiological reference standard. The latest version of CAD4TB is found to outperform all previous versions in terms of area under receiver operating curve (ROC) with respect to both Xpert and radiological reference standards. Improvements with respect to Xpert are most apparent at high sensitivity levels with a specificity of 76% obtained at 90% sensitivity. When compared with the radiological reference standard, CAD4TB v6 also outperformed previous versions by a considerable margin and achieved 98% specificity at 90% sensitivity. No substantial difference was found between the performance of CAD4TB v6 and any of the various expert observers against the Xpert reference standard. A cost and efficiency analysis on this dataset demonstrates that in a standard clinical situation, operating at 90% sensitivity, users of CAD4TB v6 can process 132 subjects per day at an average cost per screen of \$5.95 per subject, while users of version 3 process only 85 subjects per day at a cost of \$8.41 per subject. At all tested operating points version 6 is shown to be more efficient and cost effective than any other version.

## Introduction

Tuberculosis (TB) remains one of the top ten causes of death worldwide with approximately 10 million cases in 2017, causing an estimated 1.6 million deaths<sup>1</sup>. Definitive diagnosis of TB is unfeasibly time-consuming, with the gold standard of sputum culture testing being expensive and requiring several weeks for a conclusive result. TB is known to be an extremely contagious disease and prompt diagnosis and treatment are required as a means of infection control. In recent years the Xpert MTB/RIF<sup>®</sup> (GeneXpert, Cepheid, Sunnyvale, CA, USA)<sup>2</sup>, molecular test (Xpert) has become increasingly popular, with a high sensitivity and specificity<sup>2</sup>, and endorsement from the World Health Organization (WHO) since 2010. However, with the majority of TB cases occurring in resource-constrained settings, the cost of the Xpert test remains comparatively high (from \$13 in countries where concessional pricing is available<sup>3-5</sup>, and \$46-175 in private healthcare settings<sup>6</sup>). Obtaining sputum samples from large populations is additionally both time-consuming and logistically difficult while daily throughput is limited by the processing time of 2 hours for the Xpert test.

For these reasons, there is growing interest in the use of chest X-Ray (CXR) as a means of simple and efficient pre-screening of populations in advance of sputum testing<sup>7,8</sup>. While CXR is a sensitive tool for detection of pulmonary TB<sup>8</sup>, the lack of medical expertise to interpret CXR images in low-resource, high-burden settings has limited its usage in the past. This has prompted the development of analytical software capable of identifying the presence of TB from CXR images. In this study we evaluate one such software platform, CAD4TB v6, developed in association with Radboud University Medical Center,

the Netherlands. The CAD4TB software is distributed by Delft Imaging Systems and is already in use in numerous settings worldwide where its performance has been previously studied<sup>3,9-13</sup>. In 2018 version 6 of the software was released, the first version to use deep-learning technology. This version of the software can interpret a CXR image in less than 15 seconds and is designed to work on subjects from age 4 years and upwards. In this work its performance relative to previous versions and expert human observers is studied.

## Methods

### Data

The data used in this study were acquired from two purpose built TB treatment and diagnostic centers (known as Sehatmand Zindagi, "healthy life" centers) in Karachi, Pakistan between October 2013 and September 2015. Recruitment to these centers was via self-referral or through referral of individuals with presumptive TB (according to WHO screening recommendations<sup>14</sup>) from private health-care clinics in the locality. The reported symptoms of the participants were recorded including presence and duration of cough and presence of fever, haemoptysis or night sweats. Full analysis of symptoms can be obtained from previous work<sup>13</sup>. All participants underwent CXR and provided a sputum sample for Xpert testing. The CXR images were recorded digitally in dicom format. The results of the Xpert test are used as the reference standard throughout this work. This study includes data from 5565 individuals as described in Table 1.

	All n(%)	XPRT MTB/RIF	
		Positive n(%)	Negative n(%)
<b>Gender</b>			
Male	2756 (49.5)	400 (14.5)	2356 (85.5)
Female	2809 (50.5)	454 (16.2)	2355 (83.8)
<b>Age (10-101)</b>			
<=25	1525 (27.4)	356 (23.3)	1169 (76.7)
26-45	2079 (37.4)	282 (13.6)	1797 (86.4)
46+	1961 (35.2)	216 (11.0)	1745 (89.0)
<b>Cough</b>			
None	714 (12.8)	47 (6.6)	667 (93.4)
< 2 Weeks	4525 (81.3)	745 (16.5)	3780 (83.5)
> 2 Weeks	326 (5.9)	62 (19.0)	264 (81.0)
<b>Fever</b>			
Yes	4213 (75.7)	731 (17.4)	3482 (82.6)
No	1352 (24.3)	123 (9.1)	1229 (90.9)
<b>Haemoptysis</b>			
Yes	739 (13.3)	153 (20.7)	586 (79.3)
No	4826 (86.7)	701 (14.5)	4125 (85.5)
<b>Night Sweats</b>			
Yes	1732 (31.1)	339 (19.6)	1393 (80.4)
No	3833 (68.9)	515 (13.4)	3318 (86.6)

**Table 1.** Characteristics of the data from 5565 individuals included in this study.

### Observer Analysis

To evaluate and compare the performance of human experts in detecting TB from this CXR dataset, 500 scans (250 Xpert positive and 250 Xpert negative) were selected for visual examination and scoring. To ensure that the selected set was not coincidentally more or less 'difficult' than average, it was chosen such that the performance of CAD4TB v6 on the 500 scans was equivalent to that on the entire set (Area under Receiver Operating Curve (ROC) = 0.885, as described in the Results section). This was done by repeated random sampling and testing until a set was found where the CAD4TB performance met the stated requirements.

The observers were shown each of the 500 scans on a browser-based platform where zooming, panning and window-levelling were permitted as desired. The observers were aware that the images came from a high-burden setting but blinded to clinical information and to each other's scores. Each observer assigned every scan one of the following scores:

1. No TB: Scan is normal or has an abnormality not related to TB

2. Possible TB: Scan has some abnormalities, TB cannot be ruled out
3. Likely TB: Scan has abnormalities which are strongly suggestive of TB

The observer could also add free text if desired, to indicate any other observations. Five observers with various backgrounds and experience, as described below, scored all 500 selected scans.

- Observer 1: A radiologist with special interest in chest radiology and more than 30 years of experience working in the Netherlands.
- Observer 2: A public health TB-doctor in the Netherlands with 25 years experience in chest X-ray reading.
- Observer 3: A radiologist working as a consultant in chest radiology for a network of private TB diagnostic and treatment facilities in Pakistan
- Observer 4: A radiologist with specialty in chest radiology and 4 years of experience working in the Netherlands.
- Observer 5: An X-ray technician working at one of the 61 Sehatmand Zindagi health centers (static center) in Pakistan. Acquires more than 100 scans per day in this setting and operates the CAD4TB software.

### CAD4TB Analysis

CAD4TB is a software platform which uses machine-learning techniques to automatically detect TB from CXR images. The software has been trained on independent annotated datasets to recognise distinctive features of TB in CXR images. It outputs a score (0-100), which may be interpreted as the probability that the subject is suffering from active TB visible on CXR. An abnormality heatmap indicating regions which the software considers suspicious is also produced, see Figure 1. The most recent version of this platform, CAD4TB v6, released in 2018, uses deep-learning, a variant of machine-learning using deep neural networks. Deep learning has rapidly become the technique of choice in the field of computerized image interpretation and in the last decade has been repeatedly demonstrated to outperform other methods in a multitude of tasks and settings, including medical image analysis<sup>15</sup>. Four versions of CAD4TB are compared in this work (from oldest to newest: v3, v4, v5 and v6). Previous works have examined the performance of version 3<sup>3,9,10,13</sup> and version 5<sup>11,12</sup> in a variety of settings. In this work the software is run on all 5565 scans in the described dataset and the output scores are obtained and analyzed firstly with reference to the Xpert results and secondly with respect to a radiological reference standard set by expert observers. The radiological reference standard is set on the 500 scans described in the previous section which were read by 5 observers. The reference standard created identified a subject as TB positive if 3 or more of the 5 observers had scored the examination with scores 2 or 3. In this way 338 scans were marked positive and 162 negative. To compare the performance of CAD4TB v6 directly with each observer we further create 5 separate radiological reference standards as described above, but, in this case, each time we exclude a different observer. A scan is identified as TB positive if 2 or more of the remaining 4 observers gave a score of 2 or 3. Each resulting reference standard is then used to evaluate the performance of both CAD4TB v6 and the excluded observer. Confidence intervals in all cases are obtained by bootstrapping<sup>16</sup>.


### Cost Analysis

As in previous work<sup>3</sup> we perform cost analysis based on a hypothetical point-of-care testing unit with one digital radiography system and three 4-cartridge GeneXpert IV machines. The digital radiography system is operated by a trained technician and all image analysis is done by CAD4TB. It has a capacity of 300 CXR screens per day while the Xpert testing capacity is 45 tests per day.

The overall cost for an Xpert test in the 145 countries eligible for subsidised Xpert testing has been estimated at \$13.06 including equipment, resources, maintenance and consumables<sup>3</sup>. The sources for these prices remain unchanged<sup>5</sup> and the same figure is thus retained in this work. Similarly for the digital radiography system, the cost analysis used in previous work<sup>3</sup> is re-used, where equipment and running costs have been fully itemized resulting in a cost of \$1.49 per CXR screening.

Since CXR screening is many times cheaper and faster than Xpert testing, we perform cost, efficiency and sensitivity analysis of a scenario where CAD4TB identifies a proportion of subjects eligible for subsequent Xpert testing and the remainder are discharged after the CXR screen. The CAD4TB system can be operated at varying levels of sensitivity (and associated specificity), thus we perform the same analysis at four different high-sensitivity settings, to illustrate the effect on cost and efficiency at each setting, for each version of CAD4TB. The following figures are calculated at each setting:

- *s*: System sensitivity. The proportion (0-1) of Xpert-positive cases that would be **correctly** identified by CAD4TB at this operating point



**Figure 1.** Sample output from CAD4TB v6. (a) The original radiograph, (b) The radiograph with abnormality heatmap overlay. The CAD4TB score for this subject was 91.7 (0=normal, 100=most abnormal) and the Xpert test was positive.

- $p_X$ : The proportion (0-1) of cases that will be sent for subsequent Xpert testing. This is all cases that would be marked as TB positive by CAD4TB at this operating point (including some false positives).
- $C_{AVG}$ : The average cost for a case arriving at the unit.  $C_{AVG} = \$1.49 + (p_X \times \$13.06)$
- $C_{TB}$ : The average cost per TB case detected. This calculation requires an estimate of TB prevalence, for which we use the incidence in our dataset.  $C_{TB} = C_{AVG} / \frac{854}{5565}$
- $\theta$ : The daily throughput, i.e. the number of subjects that can be screened per day. While several hundred CXR screens could be performed in a day, the actual throughput is limited by the capacity of 45 Xpert screens per day in all tested scenarios and is given by  $\theta = 45/p_X$

In contrast to the study data used by Philipsen et al<sup>3</sup>, we do not have a reference standard of sputum culture testing, therefore it should be noted that the sensitivity values calculated in this work are relative to the Xpert results only. The comparison is made, thus, between a setting where only Xpert testing is available and a setting where CAD4TB pre-screening is available in addition to Xpert.


## Results

### CAD4TB Performance


The four versions of the CAD4TB software are compared in part (a) of Figure 2 with the outcome of the Xpert test as a reference standard. The sensitivity and specificity of each version of CAD4TB is obtained at multiple operating points by applying various thresholds on the output score in order to produce an ROC curve for each system. The area under the ROC curve ( $A_z$ ) is also shown for each system as an overall measure of performance. It is clear that the latest version, CAD4TB v6 demonstrates a marked improvement compared to its predecessors with notably higher sensitivities possible without loss of specificity. In version 6 the system can achieve 90% sensitivity with 76% specificity. The performances of CAD4TB versions 4 and 5 are very similar to each other on this dataset. version 4 has a marginally larger area under the curve than version 5 and shows improved specificity at lower sensitivity levels compared to both versions 5 and 6. CAD4TB v3 has the poorest performance with reduced specificity at all sensitivity settings compared to its successors.

In part (b) of Figure 2 the performances of the four versions of CAD4TB are compared with the radiological reference standard created from the 5 reader opinions. The agreement with the radiological reference standard is significantly higher than with the Xpert results. Again, CAD4TB v6 has a markedly improved performance compared to previous versions, with an  $A_z$  value of 0.987, achieving 98% specificity at 90% sensitivity. The weakest performance is that of version 3 ( $A_z=0.896$ ).

Figure 3 illustrates the performance of CAD4TB v6 and of each observer compared with the ‘consensus’ of the four other observers. In each case the scores of the observer not in the reference standard are thresholded at score values 1 and 2 to obtain two distinct operating points of sensitivity and specificity. These are plotted with the curve for CAD4TB v6 shown for comparison. CAD4TB v6 shows a statistically significant improvement in performance compared to Observer 5 (a non-physician) at high sensitivities. Otherwise the performance of CAD4TB v6 is very similar to expert observers, particularly at high sensitivities, and no observer is seen to perform significantly better than CAD4TB v6 at any operating point.



**Figure 2.** Comparing previous and current releases of CAD4TB. a) Reference = Xpert. N=5665. b) Reference = Radiological ‘Consensus’. N=500. Shaded areas represent the 95% confidence intervals for the curves shown)




**Figure 3.** Each of the 5 observers is compared against a ‘consensus’ reference standard from the remaining 4 observers. The performance of CAD4TB v6 against the same reference standard is also illustrated in each case.

### Expert Observer Analysis

As described in the previous section, observer performance is analysed by plotting two distinct operating points for comparison with the ROC curve of CAD4TB. Performance of all observers and CAD4TB v6 is illustrated in Figure 4 using Xpert testing as the reference standard. For optimal accuracy the CAD4TB curve is calculated using all 5665 cases, however we additionally show the curve using only the 500 cases selected for annotation. All observer scores are clustered in the region of the CAD4TB

curve with predominantly overlapping inter-observer 95% confidence intervals. Observer 5, the X-ray technician without formal medical/radiology training, has the weakest performance with operating points below the CAD4TB curve. Observers 1, 2 and 4, all experts from a Western setting, have operating points very close to the curve. Observer 1 retains a high sensitivity, close to 0.9, even at the higher threshold point (sensitivity=0.88), implying a greater inclination to assign score 3 (strongly suggestive of TB). The radiologist experienced working in the studied high burden setting (Observer 3) has the best performance, particularly in terms of specificity, demonstrating notably improved specificity compared to all other observers at the lower threshold (where sensitivity varies very little - from 0.96 to 0.98)



**Figure 4.** Expert observer performance compared with CAD4TB version 6, Reference=Xpert. The observers scored a set of 500 cases (250 positive, 250 negative). The CAD4TB curve is shown for both all 5665 cases (854 positive, 4711 negative), and the 500 annotated cases. (Note that the 500 cases were selected such that CAD4TB v6 Az=0.885 over the set.) The shaded region of the curves and the error-bars on observer points represent 95% confidence-intervals.

### Cost Analysis Results

The results of the analysis of cost, sensitivity and efficiency in the hypothetical point-of-care unit described in the Methods section are provided in Table 2. It is clear that CAD4TB v6 is substantially more cost-effective at all reported sensitivities when compared to previous versions with the difference becoming more evident with increasing sensitivity. CAD4TB v3 is the least cost-effective, while for this particular dataset the differences between versions 4 and 5 are marginal. Figure 5 graphically depicts the differences between versions 3 (the most commonly analysed version in the current literature) and version 6, at the four different levels of sensitivity. The figure also shows the contrast with the cost and throughput of the specified unit in the absence of CAD4TB screening.


		CAD4TB v3	CAD4TB v4	CAD4TB v5	CAD4TB v6
Sensitivity 0.80	Specificity	0.707	0.819	0.793	<b>0.820</b>
	$p_X$	37.2%	27.6%	29.9%	<b>27.5%</b>
	$C_{AVG}$	\$6.35	\$5.10	\$5.39	<b>\$5.09</b>
	$C_{TB}$	\$41.35	\$33.23	\$35.11	<b>\$33.14</b>
	$\theta$	121	<b>163</b>	151	<b>163</b>
Sensitivity 0.85	Specificity	0.659	0.770	0.761	<b>0.804</b>
	$p_X$	41.9%	32.6%	33.3%	<b>29.7%</b>
	$C_{AVG}$	\$6.97	\$5.74	\$5.84	<b>\$5.36</b>
	$C_{TB}$	\$45.39	\$37.44	\$38.05	<b>\$34.96</b>
	$\theta$	107	138	135	<b>152</b>
Sensitivity 0.90	Specificity	0.537	0.699	0.706	<b>0.760</b>
	$p_X$	53.0%	39.3%	38.7%	<b>34.1%</b>
	$C_{AVG}$	\$8.41	\$6.62	\$6.55	<b>\$5.95</b>
	$C_{TB}$	\$54.79	\$43.14	\$42.68	<b>\$38.75</b>
	$\theta$	85	115	116	<b>132</b>
Sensitivity 0.95	Specificity	0.386	0.595	0.604	<b>0.693</b>
	$p_X$	66.6%	48.8%	48.1%	<b>40.5%</b>
	$C_{AVG}$	\$10.18	\$7.87	\$7.77	<b>\$6.78</b>
	$C_{TB}$	\$66.35	\$51.26	\$50.62	<b>\$44.21</b>
	$\theta$	68	92	94	<b>111</b>
<b>Without CAD4TB</b>					
Sensitivity 1.0	Specificity	0.0			
	$p_X$	100%			
	$C_{AVG}$	\$13.06			
	$C_{TB}$	\$85.10			
	$\theta$	45			

**Table 2.** Cost analysis using various versions of CAD4TB software as a screening tool. Four operating points with sensitivities from 0.80 - 0.95 are analysed. As per the text description  $p_X$ =proportion of cases for subsequent Xpert testing,  $C_{AVG}$ =Average cost per case,  $C_{TB}$ =Average cost per TB case detected,  $\theta$ =Daily throughput at the unit. Bold font represents the optimal value per row. The last section of the table provides costings for the scenario where no CAD4TB pre-screening is used and all subjects receive Xpert testing.

## Discussion

In spite of many years of efforts to eradicate it, TB continues to be the leading cause of death from a single infectious agent worldwide. The WHO lists 30 high-burden countries which account for 87% of all cases worldwide. The availability of diagnostic solutions that are practical, affordable and efficient in these environments remains one of the greatest challenges to ending the global TB epidemic. In this work we demonstrated the efficacy of CAD4TB v6 as a pre-screening tool in high burden settings. Experiments have been carried out on a large and representative dataset, however we note that there are some limitations to the data. Firstly the utilized reference standard of Xpert test results is imperfect. The WHO estimate the pooled sensitivity and specificity values of Xpert for detection of TB as 92.5% and 98% respectively (based on 12 single centre evaluation studies)<sup>5</sup>. Nonetheless, in the absence of culture smears which are frequently too costly and time-consuming to obtain and analyse, it is common to rely on Xpert as a reference standard. Secondly, the data comprises subjects that were symptomatic upon presentation to the clinics. This implies that TB prevalence in our study may be higher than in a random population from the same setting. In particular it should be observed that the cost per notified TB case may be increased in settings with lower prevalence.

Version 6 of CAD4TB, analysed with Xpert as a reference standard, shows substantial improvement compared to previous versions in particular at higher sensitivity levels. This achievement is particularly important in the pre-screening setting where the CAD4TB score is used as a selection criterion for subsequent sputum testing and/or treatment. A WHO consensus meeting to identify targets for new TB diagnostic tools in 2014 recommended that triage tests should have a sensitivity of 90% with a specificity of 70%<sup>17</sup>. At 90% sensitivity a specificity of 76% is achieved by CAD4TB v6 with all other versions having specificities at or below 70%. In our population of 5665 individuals this gain in specificity would represent a total saving of 283




**Figure 5.** An illustration of how CAD4TB, used as a pre-screening tool, reduces costs and increases daily throughput. Results for both CAD4TB v6 and CAD4TB v3 are shown at four different sensitivity levels. The inset bar charts illustrate the average cost per screening ( $C_{avg}$ ) and the daily throughput of the unit ( $\theta$ ) for each sensitivity level and CAD4TB version. Costing and throughput in the absence of CAD4TB is also illustrated

Xpert tests.

When compared with a radiological reference standard based on expert readings the performance of all CAD4TB versions is substantially improved compared to their performances against Xpert (Figure 2). CAD4TB v6 continues to outperform the other versions by a considerable margin. Figure 3 illustrates that none of the expert observers is significantly better than the CAD4TB system (above the 95% confidence interval) when compared with a radiological reference standard based on the remaining 4 observers. The fact that performance improves when the reference standard is radiological, and is indistinguishable from human expert performance implies that a large portion of CAD4TB errors in predicting the Xpert outcome arise from sources which cannot be eliminated by improving interpretation of the radiograph. These may include erroneous Xpert results or radiographs which are difficult to interpret for both radiologists and CAD4TB alike. In such cases the presence of TB may be difficult or impossible to visualize on the radiograph or the presence of old (inactive) TB or a different pathology may be indistinguishable from active TB on the image. Some examples of these types of cases are shown in Figure 6. In some settings it is possible that the subject has already begun TB treatment in previous weeks, leading to negative sputum results but a radiograph which still has an abnormal appearance. In contrast Figure 7 shows two straightforward cases where CAD4TB and experts agreed well with the Xpert outcome.

CAD4TB is intended for use primarily in high-burden settings where radiological expertise is rarely available. For optimal results it is desirable that the system performs as well as a human observer in recognizing TB. In this work we compare the performance of CAD4TB v6 with that of five independent readers with various levels of expertise and experience in diagnosing



(a)




(b)

**Figure 6.** Cases where radiograph interpretation does not conform well with Xpert outcome. (a) An Xpert-negative case marked as TB positive (score 3) by all five observers and by CAD4TB v6 (score=100). (b) An Xpert-positive case marked with score 1 (no-TB) by 4 of the experts and score 2 by the last one. The CAD4TB score for this case is 18.7 which is not picked up as TB positive until a sensitivity of 99% is reached.



(a)



(b)

**Figure 7.** Cases where radiograph interpretation by observers and CAD4TB conforms well with Xpert outcome. (a) An Xpert-positive case marked as TB positive (score 3) by all five observers and by CAD4TB v6 (score=91.7). (b) An Xpert-negative case marked with score 1 (no-TB) by all 5 experts. The CAD4TB score for this case is 7.1 which is not picked up as TB positive until a sensitivity of 99% is reached.

TB on chest X-ray. In Figures 3 and 4 it is clear that CAD4TB has a performance well within the range of the expert observers using both Xpert and radiological reference standards. Figure 4 shows that at sensitivity levels above 80% no observer operating point is higher than the 95% confidence interval of the CAD4TB system. Notably, the system improves on the performance of observer 5 in both Figures 3 and 4. This observer is not trained as a physician or a radiologist and represents the typical skill

level that might be expected from trained system operators in high-burden settings. From these results it is clear that at the most relevant, high, sensitivity levels the performance of CAD4TB version 6 is similar to that of human experts.

The cost and efficiency analysis in Table 2 demonstrates conclusively the advantage of CAD4TB version 6 over previous versions. At a sensitivity of 90% users of CAD4TB version 6 have a throughput that is 1.6 times higher, and a cost per screen that is 1.4 times lower than users of version 3. The graphical depiction in Figure 5 illustrates the gains that version 6 achieves in both cost and efficiency at various sensitivity levels and the contrast with a scenario without any CAD4TB screening. At a very high sensitivity of 95% the cost per screened subject (\$6.78) with CAD4TB v6 is almost half the cost at a unit without CAD4TB screening (\$13.06) while the daily throughput of the unit (111) is almost 2.5 times higher. In settings where sensitivity values below 95% are acceptable the financial and capacity gains increase accordingly as shown by the inset charts on Figure 5.

In conclusion this work demonstrates that CAD4TB v6 is an accurate system, operating at the level of expert human readers in detecting TB from chest X-Ray. Used as a pre-screening system in regions where TB is endemic, CAD4TB allows for testing of much larger numbers of subjects at a fraction of the cost.

## Acknowledgements

This work was partially funded by Delft Imaging Systems. The funding body had no role in the decision to publish this study.

**Competing Interests Statement:** JM, RP, AM were in the employment of Thirona (developer of CAD4TB software) at the time of manuscript preparation. BvG receives royalties and funding from Delft Imaging Systems and Mevis Medical Solutions and stock, royalties and funding from Thirona. The other authors report no conflicts.

**Author Contributions Statement:** KM analysed system performance and prepared manuscript including most figures SSH, SMAZ, SK, AK provided images and associated data, reviewed and edited manuscript JM, RHHMP, AM Supplied output from CAD4TB system, assisted with figure preparation, reviewed and edited manuscript ETS, FA, SS, MV Participated as expert observers analysing 500 scans, reviewed and edited manuscript BvG Supervised content and development of manuscript, reviewed and edited same.

## References

1. World Health Organization, Global Tuberculosis Report. <http://apps.who.int/iris/bitstream/handle/10665/274453/9789241565646-eng.pdf> (2018).
2. Boehme, C. C. *et al.* Feasibility, diagnostic accuracy, and effectiveness of decentralised use of the Xpert MTB/RIF test for diagnosis of tuberculosis and multidrug resistance: a multicentre implementation study. *The Lancet* **377**, 1495–1505, DOI: [10.1016/S0140-6736\(11\)60438-8](https://doi.org/10.1016/S0140-6736(11)60438-8) (2011).
3. Philipsen, R. H. H. M. *et al.* Automated chest-radiography as a triage for Xpert testing in resource-constrained settings: a prospective study of diagnostic accuracy and costs. *Sci. Reports* **5**, 12215, DOI: [10.1038/srep12215](https://doi.org/10.1038/srep12215) (2015).
4. FIND negotiated product pricing. <https://www.finddx.org/find-negotiated-product-pricing/>.
5. World Health Organization Xpert MTB/RIF implementation manual. <http://apps.who.int/iris/bitstream/handle/10665/112469/9789241506704.pdf> (2014).
6. Ponnudurai, N., Denkinger, C. M., Van Gemert, W. & Pai, M. New TB tools need to be affordable in the private sector: The case study of Xpert MTB/RIF. *J. Epidemiol. Glob. Heal.* **In Press**, DOI: [10.1016/j.jegh.2018.04.005](https://doi.org/10.1016/j.jegh.2018.04.005) (2018).
7. Kranzer, K. *et al.* The benefits to communities and individuals of screening for active tuberculosis disease: a systematic review [Number 2 in the series]. *The Int. J. Tuberc. Lung Dis.* **17**, 432–446, DOI: [10.5588/ijtld.12.0743](https://doi.org/10.5588/ijtld.12.0743) (2013).
8. van't Hoog, A. H., Onozaki, I. & Lonnroth, K. Choosing algorithms for TB screening: a modelling study to compare yield, predictive value and diagnostic burden. *BMC Infect. Dis.* **14**, 532, DOI: [10.1186/1471-2334-14-532](https://doi.org/10.1186/1471-2334-14-532) (2014).
9. Melendez, J. *et al.* An automated tuberculosis screening strategy combining X-ray-based computer-aided detection and clinical information. *Sci. reports* **6**, 25265, DOI: [10.1038/srep25265](https://doi.org/10.1038/srep25265) (2016).
10. Breuninger, M. *et al.* Diagnostic Accuracy of Computer-Aided Detection of Pulmonary Tuberculosis in Chest Radiographs: A Validation Study from Sub-Saharan Africa. *PLoS ONE* **9**, e106381, DOI: [10.1371/journal.pone.0106381](https://doi.org/10.1371/journal.pone.0106381) (2014).
11. Melendez, J. *et al.* Automatic versus human reading of chest X-rays in the Zambia National Tuberculosis Prevalence Survey. *The Int. J. Tuberc. Lung Dis.* **21**, 880–886, DOI: [10.5588/ijtld.16.0851](https://doi.org/10.5588/ijtld.16.0851) (2017).
12. Melendez, J. *et al.* Accuracy of an automated system for tuberculosis detection on chest radiographs in high-risk screening. *The Int. J. Tuberc. Lung Dis.* **22**, 567–571, DOI: [10.5588/ijtld.17.0492](https://doi.org/10.5588/ijtld.17.0492) (2018).
13. Zaidi, S. M. A. *et al.* Evaluation of the diagnostic accuracy of Computer-Aided Detection of tuberculosis on Chest radiography among private sector patients in Pakistan. *Sci. Reports* **8**, 12339, DOI: [10.1038/s41598-018-30810-1](https://doi.org/10.1038/s41598-018-30810-1) (2018).

14. Systematic screening for active tuberculosis Principles and recommendations.
15. Litjens, G. *et al.* A survey on deep learning in medical image analysis. *Med. Image Analysis* **42**, 60–88, DOI: [10.1016/j.media.2017.07.005](https://doi.org/10.1016/j.media.2017.07.005) (2017).
16. Efron, B. Nonparametric standard errors and confidence intervals. *Can. J. Stat.* **9**, 139–158, DOI: [10.2307/3314608](https://doi.org/10.2307/3314608) (1981).
17. WHO. High-priority target product profiles for new tuberculosis diagnostics: report of a consensus meeting. Tech. Rep. (2014).